logo
Hundreds of NASA Employees, Past and Present, Sign Letter of Formal Dissent

Hundreds of NASA Employees, Past and Present, Sign Letter of Formal Dissent

New York Times5 days ago
A public letter from NASA employees on Monday urges leaders of the space agency not to carry out deep cuts sought by the Trump administration.
'We are compelled to speak up when our leadership prioritizes political momentum over human safety, scientific advancement and efficient use of public resources,' the employees wrote in the letter. It is addressed to Sean Duffy, the secretary of transportation, whom President Trump appointed this month as acting NASA administrator.
Cuts to NASA programs have been arbitrary and in defiance of priorities set by Congress, the NASA employees said. 'The consequences for the agency and the country alike are dire,' they wrote.
NASA did not immediately respond to a request for comment.
The NASA letter follows similar letters of criticism by federal employees at the National Institutes of Health and the Environmental Protection Agency. Dr. Jay Bhattacharya, the N.I.H. director, said he welcomed respectful dissent, but the E.P.A. placed 144 employees who signed that agency's letter on leave.
'We're all scared that we're going to get laid off,' said Monica Gorman, an operations research analyst at the NASA Goddard Space Flight Center in Greenbelt, Md. 'We're scared of retaliation. We huddle in the bathroom. We go to the bathroom to talk to each other, and look under the stalls to make sure that no one else is there before we talk.'
Ms. Gorman is one of 287 current and former NASA employees who signed the letter, although more than half did so anonymously. More than 15,000 people work at the space agency. Prominent scientists outside of NASA, including 20 Nobel Prize winners, also offered their names in support.
Read the NASA 'Voyager Declaration' Letter of Dissent
Hundreds of current and ex-employees of NASA signed a formal dissent letter protesting the Trump administration's proposed cuts to the agency.
Want all of The Times? Subscribe.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

EU chief to meet Trump in Scotland in push to avoid a transatlantic trade war
EU chief to meet Trump in Scotland in push to avoid a transatlantic trade war

CNBC

time11 minutes ago

  • CNBC

EU chief to meet Trump in Scotland in push to avoid a transatlantic trade war

European Commission President Ursula von der Leyen will meet with U.S. President Donald Trump in Scotland over the weekend, seeking to reach a framework trade agreement shortly before a 30% tariff on EU imports comes into effect. In a post on social media platform X on Friday, the EU's von der Leyen said she had agreed to meet with the U.S. president on Sunday "to discuss transatlantic trade relations, and how we can keep them strong." Trump later confirmed the meeting would take place as he arrived in Scotland on Friday evening, saying "we'll see if we can make a deal." "I think we have a good 50/50 chance. That's a lot," he added. It comes amid a sense of growing optimism about the prospect of a tariff breakthrough, with sources telling CNBC that the current base-case scenario for a deal includes a 15% tariff on EU imports to the U.S. Trump has threatened to impose tariffs of 30% on EU goods from Aug.1, prompting the EU to consider countermeasures as part of its response. The U.S. and EU have the largest bilateral trade and investment relationship in the world, representing almost 30% of global trade in goods and services, and accounting for 43% of global gross domestic product (GDP), according to EU figures. Trump's four-day and golf-heavy Scotland visit is also expected to see him hold an informal meeting with U.K. Prime Minister Keir Starmer. Unlike the EU, the U.K. recently struck a trade deal with the Trump administration, one which is centered on a 10% tariff baseline on British goods arriving in the U.S. Hopes of the U.S. and EU averting a transatlantic trade war from Aug. 1 have been buoyed at least in part by the recent announcement of a framework agreement between the U.S. and Japan. The U.S.-Japan deal, which Trump described in a social media post as "perhaps the largest Deal ever made," includes a baseline tariff rate of 15%. Jack Allen-Reynolds, deputy chief euro zone economist at Capital Economics, said Friday that a similar framework for the EU might be seen as case where a bad deal is better than no deal. "Reports this week suggest that the EU and US are on the brink of agreeing a trade deal with a 15% baseline tariff on US imports from the bloc. It's hard to spin it as a good deal, but it would at least avoid much higher US tariffs and retaliation from the EU," Allen-Reynolds said in a research note.

China's Xi Makes Trump Wait for Leader Talks
China's Xi Makes Trump Wait for Leader Talks

Newsweek

time11 minutes ago

  • Newsweek

China's Xi Makes Trump Wait for Leader Talks

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The White House has been optimistic about the prospects for an in-person summit with Chinese President Xi Jinping—the first of President Donald Trump's second term. Yet analysts say the Chinese leader is likely holding out for concrete deliverables before agreeing to the high-profile meeting. All Eyes on Sweden Trump dramatically escalated the trade war with the world's second-largest economy in April, rolling out sweeping new tariffs that prompted China to respond with its own export duties and other measures. While Trump has said that "the confines of a deal" are in place ahead of a third round of talks between U.S. and Chinese negotiators, set for Sweden next week, several contentious issues remain unresolved. These include ongoing U.S. curbs on advanced chip exports to China and persistent geopolitical friction over influence in Asia and Beijing's threats toward Taiwan. Newsweek reached out to the White House and Chinese embassy in the U.S. via email for comment. Europe's Role Patrick Cronin, Asia-Pacific security chair at the Hudson Institute, told Newsweek: "A Xi-Trump summit is highly probable, but withholding final approval until Beijing can button down more information and as many concessions as possible is no doubt part of Xi's calculus." "What China and the United States can each negotiate with the EU will also help inform the China-US trade bargain that will be at the heart of any Xi-Trump summit," Cronin said. After months of efforts with dozens of countries, the White House recently secured a handful of deals with Japan, Vietnam, the Philippines and Indonesia, Cronin added. In a picture combination created on May 14, 2020, Chinese President Xi Jinping, left, and U.S. President Donald Trump are shown. In a picture combination created on May 14, 2020, Chinese President Xi Jinping, left, and U.S. President Donald Trump are shown. Dan Kitwood, Nicholas Kamm/AFP via Getty Images Among the deals Trump hopes to achieve is with the EU—a traditionally U.S.-aligned bloc that has become increasingly alienated by Trump's unpredictable trade moves and controversial domestic policies. Analysts say China has been seeking to exploit this rift and achieve a thaw in ties with Brussels that has deteriorated over issues like alleged Chinese market flooding with state-subsidized electric vehicles, human rights concerns and Beijing's support for Russia amid the war in Ukraine. Sean King, an Asia scholar and senior vice president at Park Strategies, told Newsweek: "PRC [People's Republic of China] leaders have long seen Europe as a comparatively easier mark, as the continent doesn't have America's Asian security concerns and obligations." He added, "It's probably better for Trump to first line up what he says are trade deals with friends and allies before going for the big one with Beijing." While European Commission President Ursula von der Leyen's visit to Beijing this week yielded a memorandum of understanding on climate change and an agreement to facilitate rare-earth exports, analysts note that a fundamental shift in EU-China ties remains elusive. Timetable Uncertain U.S. Secretary of State Marco Rubio, visiting Malaysia earlier this month for meetings with his Chinese counterpart Wang Yi, said that "the odds are high" a Trump-Xi summit will take place by the end of the year. Rosemary Foot, professor and senior research fellow at the University of Oxford's Department of Politics and International Relations, told Newsweek it's unlikely Xi is counting on Europe as leverage in his dealings with the White House. "I think that it is to do with China's more general approach to the Trump administration which is to wait for some intention to offer a serious deliverable from the meeting and perhaps also to paint President Trump as supplicant," she said. Trump and Xi last met in 2019 at the G20 summit in Osaka, Japan.

Cogent Biosciences Rated as a Buy at Citi on Robust Pipeline
Cogent Biosciences Rated as a Buy at Citi on Robust Pipeline

Yahoo

time24 minutes ago

  • Yahoo

Cogent Biosciences Rated as a Buy at Citi on Robust Pipeline

Cogent Biosciences, Inc. (NASDAQ:COGT) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 18, Citi raised its price target of the stock to $22 from $15 while maintaining a 'Buy' rating. A doctor reading the results of a Phase 2 clinical trial of treatments for cancer, infectious diseases and autoimmune and inflammatory diseases. The price target hike comes as the company delivers top-line results from bezuclastinib (bezu) in non-advanced systemic mastocytosis (NonAdvSM). According to Citi, investors are increasingly viewing bezuclastinib as an improvement over Blueprint's Ayvakit. The research firm expects the company to deliver positive symptom and biomarker data at ASH in December. Beyond bezuclastinib, Cogent Biosciences is also advancing its other pipeline candidates. The company plans to release advanced systemic mastocytosis (AdvSM) data from the APEX trial in the second half of the year. It will also provide results from the PEAK trial for gastrointestinal stromal tumors (GIST). Cogent Biosciences, Inc. (NASDAQ:COGT) is a biotechnology company that develops precision therapies for genetically defined diseases. It focuses on diseases caused by genetic mutations. Its lead program, bezuclastinib, is a tyrosine kinase inhibitor designed to target the KIT D816V mutation, which drives systemic mastocytosis, as well as other mutations in KIT exon 17. While we acknowledge the potential of COGT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Goldman Sachs REIT Stocks: Top 12 Stock Picks. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store